Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oligopin is a highly purified standardized dry extract derived from the bark of the French maritime pine tree (Pinus pinaster). It is rich in oligomeric procyanidins (OPCs), bioflavonoids, catechins, and organic acids. The primary mechanism of action is its potent antioxidant activity—neutralizing free radicals and reducing oxidative stress. Oligopin also exhibits anti-inflammatory properties and has been shown to support cardiovascular health by increasing nitric oxide synthesis in blood vessel endothelium, promoting vasodilation and optimal circulation. Clinical studies indicate it is well-tolerated with a high safety margin; it has been evaluated for use in conditions such as cardiovascular disease and polycystic ovary syndrome (PCOS), though evidence for efficacy in PCOS is lacking[4][5][7]. Developed using advanced extraction techniques to ensure high purity and low tannin content compared to other pine bark extracts, Oligopin’s main applications are as a dietary supplement for antioxidant support, vascular health, skin health, urinary tract health, muscle function, post-menopausal wellness, vein health, and general reduction of oxidative stress[6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Oligopin.